======= IRF8 =======
== Gene Information ==
* **Official Symbol**: IRF8
* **Official Name**: interferon regulatory factor 8
* **Aliases and Previous Symbols**: N/A
* **Entrez ID**: [[https://www.ncbi.nlm.nih.gov/gene/?term=3394|3394]]
* **UniProt**: [[https://www.uniprot.org/uniprot/Q02556|Q02556]]
* **Interactions**: [[https://thebiogrid.org/search.php?search=IRF8&organism=9606|BioGRID]]
* **PubMed articles**: [[https://www.ncbi.nlm.nih.gov/pubmed/?term=gene%20IRF8|Open PubMed]]
* **OMIM**: [[https://omim.org/entry/601565|Open OMIM]]
== Function Summary ==
* **Entrez Summary**: Interferon consensus sequence-binding protein (ICSBP) is a transcription factor of the interferon (IFN) regulatory factor (IRF) family. Proteins of this family are composed of a conserved DNA-binding domain in the N-terminal region and a divergent C-terminal region that serves as the regulatory domain. The IRF family proteins bind to the IFN-stimulated response element (ISRE) and regulate expression of genes stimulated by type I IFNs, namely IFN-alpha and IFN-beta. IRF family proteins also control expression of IFN-alpha and IFN-beta-regulated genes that are induced by viral infection. [provided by RefSeq, Jul 2008].
* **UniProt Summary**: Plays a role as a transcriptional activator or repressor (PubMed:25122610). Specifically binds to the upstream regulatory region of type I IFN and IFN-inducible MHC class I genes (the interferon consensus sequence (ICS)). Plays a negative regulatory role in cells of the immune system. Involved in CD8(+) dendritic cell differentiation by forming a complex with the BATF-JUNB heterodimer in immune cells, leading to recognition of AICE sequence (5'-TGAnTCA/GAAA-3'), an immune-specific regulatory element, followed by cooperative binding of BATF and IRF8 and activation of genes (By similarity). {ECO:0000250|UniProtKB:P23611, ECO:0000269|PubMed:25122610}.
|IRF-3|
|IRF|
|defense response to protozoan|
|response to protozoan|
|positive regulation of interleukin-12 production|
|regulation of interleukin-12 production|
|positive regulation of interferon-gamma production|
|type I interferon signaling pathway|
|cellular response to type I interferon|
|response to type I interferon|
|interferon-gamma-mediated signaling pathway|
|regulation of interferon-gamma production|
|cellular response to interferon-gamma|
|response to interferon-gamma|
|cellular response to lipopolysaccharide|
|cellular response to molecule of bacterial origin|
|cellular response to biotic stimulus|
|myeloid cell differentiation|
|DNA-binding transcription repressor activity, RNA polymerase II-specific|
|autophagy|
|process utilizing autophagic mechanism|
|response to lipopolysaccharide|
|response to molecule of bacterial origin|
|phagocytosis|
|defense response to bacterium|
|positive regulation of cytokine production|
|RNA polymerase II proximal promoter sequence-specific DNA binding|
|cellular response to lipid|
|hemopoiesis|
|hematopoietic or lymphoid organ development|
|immune system development|
|cytokine-mediated signaling pathway|
|response to bacterium|
|regulation of cytokine production|
|innate immune response|
|response to lipid|
|negative regulation of transcription by RNA polymerase II|
|defense response to other organism|
|cellular response to cytokine stimulus|
|cellular response to oxygen-containing compound|
|response to cytokine|
|negative regulation of transcription, DNA-templated|
|positive regulation of transcription by RNA polymerase II|
|negative regulation of nucleic acid-templated transcription|
|negative regulation of RNA biosynthetic process|
|response to other organism|
|response to external biotic stimulus|
|response to biotic stimulus|
|negative regulation of RNA metabolic process|
|defense response|
|negative regulation of cellular macromolecule biosynthetic process|
|negative regulation of nucleobase-containing compound metabolic process|
|negative regulation of macromolecule biosynthetic process|
|negative regulation of cellular biosynthetic process|
|positive regulation of transcription, DNA-templated|
|negative regulation of biosynthetic process|
|response to oxygen-containing compound|
|DNA-binding transcription factor activity, RNA polymerase II-specific|
|positive regulation of nucleic acid-templated transcription|
|positive regulation of RNA biosynthetic process|
|negative regulation of gene expression|
|positive regulation of RNA metabolic process|
|positive regulation of multicellular organismal process|
|cellular catabolic process|
|immune response|
|positive regulation of nucleobase-containing compound metabolic process|
|positive regulation of macromolecule biosynthetic process|
|vesicle-mediated transport|
|positive regulation of cellular biosynthetic process|
|positive regulation of gene expression|
|positive regulation of biosynthetic process|
\\
=== CRISPR Data ===
^Screen^Score^
|[[:results:exp516|Pyrazinamide 100μM R08 exp516]]|-2.17|
No correlation found to any other genes in chemogenomics.
Global Fraction of Cell Lines Where Essential: 2/739
^Tissue^Fraction Of Cell Lines Where Essential^
|1290807.0|0/1|
|909776.0|0/1|
|bile duct|0/28|
|blood|2/28|
|bone|0/26|
|breast|0/33|
|central nervous system|0/56|
|cervix|0/4|
|colorectal|0/17|
|esophagus|0/13|
|fibroblast|0/1|
|gastric|0/16|
|kidney|0/21|
|liver|0/20|
|lung|0/75|
|lymphocyte|0/16|
|ovary|0/26|
|pancreas|0/24|
|peripheral nervous system|0/16|
|plasma cell|0/15|
|prostate|0/1|
|skin|0/24|
|soft tissue|0/9|
|thyroid|0/2|
|upper aerodigestive|0/22|
|urinary tract|0/29|
|uterus|0/5|
== Essentiality in NALM6 ==
* **Essentiality Rank**: 8952
* **Expression level (log2 read counts)**: 1.31
{{:chemogenomics:nalm6 dist.png?nolink |}}